SG11201811152YA - Uses of extracellular vesicle comprising a fusion protein having fc binding capacity - Google Patents

Uses of extracellular vesicle comprising a fusion protein having fc binding capacity

Info

Publication number
SG11201811152YA
SG11201811152YA SG11201811152YA SG11201811152YA SG11201811152YA SG 11201811152Y A SG11201811152Y A SG 11201811152YA SG 11201811152Y A SG11201811152Y A SG 11201811152YA SG 11201811152Y A SG11201811152Y A SG 11201811152YA SG 11201811152Y A SG11201811152Y A SG 11201811152YA
Authority
SG
Singapore
Prior art keywords
evs
international
engineered
extracellular vesicle
fusion protein
Prior art date
Application number
SG11201811152YA
Inventor
André Görgens
Dhanu Gupta
Oscar WIKLANDER
Original Assignee
Evox Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evox Therapeutics Ltd filed Critical Evox Therapeutics Ltd
Publication of SG11201811152YA publication Critical patent/SG11201811152YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A61K47/6913—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome the liposome being modified on its surface by an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/554—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being a biological cell or cell fragment, e.g. bacteria, yeast cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/705—Fusion polypeptide containing domain for protein-protein interaction containing a protein-A fusion

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 111111H1110111111111111111101111101001111110111H1111111111110111111111110111111 Organization International Bureau (10) International Publication Number (43) International Publication Date .....0\"\" WO 2018/015539 Al 25 January 2018 (25.01.2018) WI P0 I P C T (51) International Patent Classification: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, A61K 39/395 (2006.01) DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, (21) International Application Number: HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, PCT/EP2017/068486 KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (22) International Filing Date: OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, 21 July 2017 (21.07.2017) SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (25) Filing Language: English (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (30) Priority Data: GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, 1612643.5 21 July 2016 (21.07.2016) GB UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, (71) Applicant: EVOX THERAPEUTICS LTD [GB/GB]; EE, ES, FL FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, 2nd Floor, King Charles Hosue, Park End Street, Oxford MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, Oxfordshire OX1 1JD (GB). TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, (72) Inventors: GORGENS, Andre; Domarvagen 18, KM, ML, MR, NE, SN, TD, TG). SE-14162 Huddinge (SE). GUPTA, Dhanu; Myrstuguva- gen 147, Varby, Huddinge, 143 32 Stockholm (SE). WIK- Published: _ LANDER, Oscar; Greta Garbos vag 21B, Solna, 16940 — with international search report (Art. 21(3)) Sweden (SE). — before the expiration of the time limit for amending the claims and to be republished in the event of receipt of = (74) Agent: COOLEY (UK) LLP; Dashwood, 69 Old Broad amendments (Rule 48.2(h)) Street, London Greater London EC2M 1QS (GB). — with sequence listing part of description (Rule 5.2(a)) = (81) Designated States (unless otherwise indicated, for every = kind of national protection available): AE, AG, AL, AM, = = AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, = = (54) Title: USES OF EXTRACELLULAR VESICLE COMPRISING A FUSION PROTEIN HAVING FC BINDING CAPACITY (57) : The present invention pertains to engineered extracel- = _ lular vesicles(EVs) for use in a variety of research, diagnostic, imag- Fc binder domain ing and therapeutic applications. The EVs are engineered to enable in- corporation and surface display of various proteins of interest, which = = — Exosomal protein may be exogenous and/or endogenous in nature. The coating of EVs is achieved through inventive protein engineering of EV polypeptides, and the present invention thus relates to methods for coating of EVs, EVs per se, as well kits, detection methods, diagnostic applications, • „„\‘ imaging and delivery methods based on said engineered EVs. — = _ _ = = `, i f — = = \ / / \ \ _ \ \ ,,,z Lipid bilayer 1-1 \ .4 Lumen 01 en ir) ir) Extracellular vesicle Il 0 _.... ,—, c:::, Figure 1 ei 0
SG11201811152YA 2016-07-21 2017-07-21 Uses of extracellular vesicle comprising a fusion protein having fc binding capacity SG11201811152YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1612643.5A GB2552473A (en) 2016-07-21 2016-07-21 Surface decoration of extracellular vesicles
PCT/EP2017/068486 WO2018015539A1 (en) 2016-07-21 2017-07-21 Uses of extracellular vesicle comprising a fusion protein having fc binding capacity

Publications (1)

Publication Number Publication Date
SG11201811152YA true SG11201811152YA (en) 2019-01-30

Family

ID=56894359

Family Applications (4)

Application Number Title Priority Date Filing Date
SG11201811151PA SG11201811151PA (en) 2016-07-21 2017-07-21 Extracellular vesicle comprising a fusion protein having fc binding capacity
SG11201811152YA SG11201811152YA (en) 2016-07-21 2017-07-21 Uses of extracellular vesicle comprising a fusion protein having fc binding capacity
SG10202100598RA SG10202100598RA (en) 2016-07-21 2017-07-21 Uses of Extracellular Vesicle Comprising a Fusion Protein Having FC Binding Capacity
SG10202100597TA SG10202100597TA (en) 2016-07-21 2017-07-21 Extracellular Vesicle Comprising a Fusion Protein Having FC Binding Capacity

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201811151PA SG11201811151PA (en) 2016-07-21 2017-07-21 Extracellular vesicle comprising a fusion protein having fc binding capacity

Family Applications After (2)

Application Number Title Priority Date Filing Date
SG10202100598RA SG10202100598RA (en) 2016-07-21 2017-07-21 Uses of Extracellular Vesicle Comprising a Fusion Protein Having FC Binding Capacity
SG10202100597TA SG10202100597TA (en) 2016-07-21 2017-07-21 Extracellular Vesicle Comprising a Fusion Protein Having FC Binding Capacity

Country Status (12)

Country Link
US (3) US11236143B2 (en)
EP (3) EP3487529A1 (en)
JP (4) JP7140743B2 (en)
KR (2) KR20190032479A (en)
CN (2) CN109689097B (en)
AU (2) AU2017300035A1 (en)
BR (2) BR112019001108A2 (en)
CA (2) CA3031186A1 (en)
GB (1) GB2552473A (en)
MX (2) MX2019000863A (en)
SG (4) SG11201811151PA (en)
WO (2) WO2018015539A1 (en)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2618821A4 (en) 2010-09-24 2014-08-13 Brigham & Womens Hospital Nanostructured gels capable of controlled release of encapsulated agents
GB2552774A (en) * 2016-07-12 2018-02-14 Evox Therapeutics Ltd EV-Mediated delivery of binding protein-small molecule conjugates
GB2552473A (en) * 2016-07-21 2018-01-31 Evox Therapeutics Ltd Surface decoration of extracellular vesicles
US11020410B2 (en) 2017-02-03 2021-06-01 The Brigham And Women's Hospital, Inc. Self-assembled gels formed with anti-retroviral drugs, prodrugs thereof, and pharmaceutical uses thereof
GB2597623A (en) 2017-08-07 2022-02-02 Univ California Platform for generating safe cell therapeutics
GB201717446D0 (en) * 2017-10-24 2017-12-06 Evox Therapeutics Ltd Affinity purification of engineering extracellular vesicles
GB201804291D0 (en) * 2018-03-16 2018-05-02 Evox Therapeutics Ltd Cell-mediated exosome delivery
AU2019247375B2 (en) 2018-04-04 2022-08-04 Alivio Therapeutics, Inc. Self-assembled gels for controlled delivery of biologics and methods of making thereof
CN110655585A (en) * 2018-06-28 2020-01-07 中央研究院 Synthetic polypeptides and uses thereof
EP3823983A4 (en) 2018-07-20 2022-05-18 The Board of Trustees of the Leland Stanford Junior University Soluble polypeptides and methods of using same for inhibiting leukemia inhibitory factor activity
KR20210045409A (en) 2018-08-14 2021-04-26 에버사이트 게엠베하 Target specific extracellular vesicles
CN108998402B (en) * 2018-08-28 2020-05-29 江南大学 Recombinant bacillus subtilis and construction method and application thereof
US20210317479A1 (en) 2018-09-06 2021-10-14 The Broad Institute, Inc. Nucleic acid assemblies for use in targeted delivery
EP3850104A4 (en) * 2018-10-19 2022-07-06 Ohio State Innovation Foundation Extracellular vesicles for targeted therapies against myeloid-derived suppressor cells
AU2019361193A1 (en) * 2018-10-19 2021-05-20 Ohio State Innovation Foundation Nanocarriers for lung inflammation therapy
SG11202103775PA (en) * 2018-11-16 2021-05-28 Evox Therapeutics Ltd Extracellular vesicles for replacement of urea cycle proteins & nucleic acids
EP3904385A4 (en) * 2018-12-27 2023-04-19 Akeso Biopharma, Inc. Antibody against human il-4ra and use thereof
KR20210142097A (en) * 2019-02-04 2021-11-24 코디악 바이오사이언시즈, 인크. Membrane protein scaffold for exosome manipulation
US20220218842A1 (en) 2019-05-06 2022-07-14 Thomas Malcolm Tailored hypoimmune nanovesicular delivery systems for cancer tumors
CA3143327A1 (en) * 2019-06-13 2020-12-17 J. Keith Joung Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells
WO2020249757A1 (en) * 2019-06-14 2020-12-17 Philogen S.P.A Immunoconjugates comprising a single chain diabody and interleukin-15 or interleukin-15 and a sushi domain of interleukin-15 receptor alpha
EP3986429A4 (en) * 2019-06-21 2023-07-19 Entelexo Biotherapeutics Inc. Platforms, compositions, and methods for therapeutics delivery
CN116171163A (en) * 2019-08-06 2023-05-26 俄亥俄州国家创新基金会 Therapeutic extracellular vesicles
EP3973969A4 (en) * 2019-09-02 2023-07-12 Kyungpook National University Industry-Academic Cooperation Foundation Composition for preventing or treating cancer, containing il-2 surface expression-extracellular vesicles as active ingredient
CN112941028A (en) * 2019-12-09 2021-06-11 上海细胞治疗集团有限公司 Nano antibody gene modified mesenchymal stem cell and preparation method and application thereof
KR20220139926A (en) 2020-02-05 2022-10-17 다이아뎀 바이오쎄라퓨틱스 인크 artificial synapse
US20230149319A1 (en) * 2020-04-13 2023-05-18 City Of Hope Cell-receptor targeted exosomes
CN111544453B (en) * 2020-04-27 2021-01-22 高连如 Mixed stem cell injection containing three angiogenesis attributes and preparation method thereof
CN111560352B (en) * 2020-06-02 2023-03-24 新疆农业大学 Virus-like vesicle and preparation method and application thereof
CN111905105B (en) * 2020-07-02 2023-05-05 华南师范大学 Protein nano-drug for cancer targeted therapy and preparation method thereof
CN112111513A (en) * 2020-07-17 2020-12-22 深圳市第二人民医院 Preparation method of novel coronavirus vaccine based on exosome platform
CN113967254B (en) * 2020-08-04 2022-08-12 华南理工大学 Cell membrane coated nano aptamer for multi-specific antibody delivery and application
US20240299529A1 (en) * 2020-08-05 2024-09-12 Ohio State Innovation Foundation Adapter polypeptides and methods of using the same
CN112285195B (en) * 2020-10-27 2021-08-10 江南大学 Characteristic glycoprotein marker of milk exosome and characteristic marker separation method of milk exosome
WO2022149779A1 (en) * 2021-01-11 2022-07-14 주식회사 엑소코바이오 Exosome comprising overexpressed fc receptor or portion thereof, and method for preparing same
KR102252325B1 (en) * 2021-01-14 2021-05-14 이장호 Production Methods of Immune-tolerant Extracellular Vesicles containing fetal-derived primal immunoglobulins
WO2022158836A1 (en) * 2021-01-21 2022-07-28 주식회사 엑소코바이오 Recombinant exosome comprising fc receptor or portion thereof to which target protein or peptide is fusible, and use thereof
US20240218046A1 (en) * 2021-04-14 2024-07-04 Anjarium Biosciences Ag Fc-derived polypeptides
EP4323394A2 (en) * 2021-04-14 2024-02-21 Anjarium Biosciences AG Peptides, nanovesicles, and uses thereof for drug delivery
GB202107182D0 (en) * 2021-05-19 2021-06-30 Evox Therapeutics Ltd Nanoparticle delivery system for production of engineered extracellular vesicles
CN113599516B (en) * 2021-08-16 2022-02-18 上海蒙彼利生物技术有限公司 Method for preparing exosome and application of pharmaceutical composition thereof in tissue repair
CN117916379A (en) * 2021-09-08 2024-04-19 株式会社梦想实验室 Plasmid platform for stable expression and delivery of biomolecules
CN113897387B (en) * 2021-10-09 2023-09-05 深圳市汉科生命工程有限公司 Preparation method and application of gene recombinant MSC (moving bed memory) with hair regeneration promoting function and exosome-like nanomaterial thereof
US20230211009A1 (en) 2021-12-03 2023-07-06 China Medical University Production of exosomes and uses thereof
CN114107253B (en) * 2021-12-17 2024-03-15 复旦大学附属华山医院 System and method for gene editing by using engineering cells
CN114236113B (en) * 2021-12-21 2023-07-21 南京农业大学 2, 4-drop instant immunosensor
WO2023133425A1 (en) * 2022-01-04 2023-07-13 The Broad Institute, Inc. Compositions and methods for delivering cargo to a target cell
WO2023196586A1 (en) * 2022-04-07 2023-10-12 The Regents Of The University Of Michigan Methods and devices for screening extracellular vesicles
WO2024064748A2 (en) * 2022-09-20 2024-03-28 North Carolina State University Compositions and methods related to exosomal delivery of therapeutic agents
CN116179582A (en) * 2022-09-27 2023-05-30 南京医事达生物科技有限公司 Preparation method and application of universal gene recombinant protein A affinity purification filler
CN117802045A (en) * 2022-09-30 2024-04-02 北京恩康医药有限公司 Construction and application of engineering extracellular vesicles

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4090299A (en) * 1998-05-20 1999-12-06 Sdg, Inc. Liposomal delivery complex
US20040241176A1 (en) * 2000-04-27 2004-12-02 Ap Cells. Inc. Method of producing membrane vesicles
US20070128117A1 (en) * 2003-02-04 2007-06-07 Bracco International B.V. Ultrasound contrast agents and process for the preparation thereof
JP2007295929A (en) 2006-04-05 2007-11-15 Geno Membrane:Kk Canine bsep gene
NZ584306A (en) * 2007-08-30 2012-10-26 Paladin Labs Inc Antigenic compositions and use of same in the targeted delivery of nucleic acids
AU2008303057B2 (en) * 2007-09-24 2014-09-04 The University Of Queensland Molecular delivery vesicle
CN102497887A (en) 2009-04-17 2012-06-13 Isis创新公司 Composition for delivery of genetic material
CA2822366A1 (en) * 2010-12-23 2012-06-28 Janssen Biotech, Inc. Active protease-resistant antibody fc mutants
DK2675474T3 (en) * 2011-02-15 2019-04-23 Vaxiion Therapeutics Llc THERAPEUTIC COMPOSITIONS AND PROCEDURES FOR TARGETED ADMINISTRATION OF BIOACTIVE MOLECULES BY BACK-TERIAL MINICLES BASED ON ANTIBODY AND FC-CONTAINING TAR-GETING MOLECULES
GB201121069D0 (en) 2011-12-07 2012-01-18 Isis Innovation Delivery system
GB201121070D0 (en) * 2011-12-07 2012-01-18 Isis Innovation composition for delivery of biotherapeutics
ES2662326T5 (en) * 2013-04-12 2021-08-04 Evox Therapeutics Ltd Therapeutic delivery vesicles
WO2015002956A1 (en) 2013-07-01 2015-01-08 Ohio State Innovation Foundation Exosome delivery system
US10538570B2 (en) * 2013-09-30 2020-01-21 Northwestern University Targeted and modular exosome loading system
EP3057662A4 (en) 2013-10-17 2017-03-29 Children's Hospital Los Angeles Antibody dependent exosome therapy
WO2015143113A1 (en) * 2014-03-20 2015-09-24 Barb Ariel Cohen Preparations of derived extracellular vesicles, assays, and methods to modify therapeutic outcomes using such preparations
GB2552473A (en) * 2016-07-21 2018-01-31 Evox Therapeutics Ltd Surface decoration of extracellular vesicles

Also Published As

Publication number Publication date
KR20190032479A (en) 2019-03-27
EP4299137A3 (en) 2024-04-10
AU2017300035A1 (en) 2019-02-07
CA3031186A1 (en) 2018-01-25
EP3487528B1 (en) 2023-08-30
SG10202100597TA (en) 2021-02-25
US20220098267A1 (en) 2022-03-31
JP2019524745A (en) 2019-09-05
EP4299137A2 (en) 2024-01-03
SG10202100598RA (en) 2021-02-25
WO2018015535A1 (en) 2018-01-25
BR112019001108A2 (en) 2019-07-02
CN109689097A (en) 2019-04-26
KR20190032480A (en) 2019-03-27
WO2018015539A1 (en) 2018-01-25
MX2019000861A (en) 2019-09-04
GB201612643D0 (en) 2016-09-07
MX2019000863A (en) 2019-09-04
US11236143B2 (en) 2022-02-01
EP3487529A1 (en) 2019-05-29
US20200109183A1 (en) 2020-04-09
US20230181757A1 (en) 2023-06-15
JP2023026440A (en) 2023-02-24
JP7254016B2 (en) 2023-04-07
SG11201811151PA (en) 2019-01-30
CA3031183A1 (en) 2018-01-25
JP7140743B2 (en) 2022-09-21
GB2552473A (en) 2018-01-31
KR102636776B1 (en) 2024-02-15
EP3487528A1 (en) 2019-05-29
BR112019001099A2 (en) 2019-06-25
CN109689098A (en) 2019-04-26
JP2022117998A (en) 2022-08-12
CN109689097B (en) 2023-01-03
AU2017299214A1 (en) 2019-02-07
JP2019523407A (en) 2019-08-22

Similar Documents

Publication Publication Date Title
SG11201811152YA (en) Uses of extracellular vesicle comprising a fusion protein having fc binding capacity
SG11201811150WA (en) Ev-mediated delivery of binding protein-small molecule conjugates
SG11201810116VA (en) Exosomes comprising therapeutic polypeptides
SG11201908719QA (en) Biomarkers and car t cell therapies with enhanced efficacy
SG11201811148SA (en) Cell penetrating peptide (cpp)-mediated ev loading
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201811149TA (en) METABOLIC DRUG LOADING OF EVs
SG11201805950UA (en) Self-assembled nanostructures and separation membranes comprising aquaporin water channels and methods of making and using them
SG11201805442XA (en) Compositions and methods related to multimodal therapeutic cell systems for immune indications
SG11201804161VA (en) Compositions comprising bacterial strains
SG11201804118VA (en) Compositions comprising bacterial strains
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201804162WA (en) Compositions comprising bacterial strains
SG11201807912SA (en) Vaccine against rsv
SG11201900163PA (en) Macrocycle kinase inhibitors
SG11201810628XA (en) Nasal pharmaceutical compositions with a porous excipient
SG11201803920TA (en) Compounds and compositions useful for treating disorders related to ntrk
SG11201408054RA (en) Pegylated oxm variants
SG11201810429UA (en) Anti-cd19 antibody formulations
SG11201903012RA (en) Anti-c1s antibodies and methods of use thereof
SG11201808710UA (en) Novel immunogenic cd1d binding peptides
SG11201808108XA (en) Synthesis of indazoles
SG11201806544XA (en) Compounds and methods of treating rna-mediated diseases
SG11201907208XA (en) Radiolabeled anti-lag3 antibodies for immuno-pet imaging
SG11201808686VA (en) Synthesis of indazoles